Trial Profile

Phase I/II Study of Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Carboplatin; Etoposide
Indications Small cell lung cancer
Focus Adverse reactions

Most Recent Events

26 Jan 2017 Status changed from active, no longer recruiting to discontinued.
22 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
17 Jan 2014 Planned end date changed from 1 Sep 2013 to 1 Sep 2015 as per According to ClinicalTrials.gov, the estimated completion date is July 2018 and the final data collection date for primary outcome is July 2017 .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com